{"entity":{"id":"nct07103668","kind":"trial","name":"A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients","aka":[],"tldr":"A phase 3 trial of CAR T cells in gastric & gastro-oesophageal junction cancer, run by Suzhou Immunofoco Biotechnology Co., Ltd, now recruiting.","summary":"A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients is a phase 3 interventional study registered as NCT07103668 by Suzhou Immunofoco Biotechnology Co., Ltd, with 150 participants planned, started 2025-08-06 and due to reach its primary completion in 2027-05-31. Interventions recorded: CAR T cells and Control.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07103668","url":"https://clinicaltrials.gov/study/NCT07103668"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["gastric"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07103668","phase":"3","setting":"An Open-label, Randomized, Comparative Phase III Study Including Patients With CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer.","sponsor":"Suzhou Immunofoco Biotechnology Co., Ltd","enrolled":150,"outcomes":[]},"route":"/trials/nct07103668/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"}]}}